SCM
TRDA icon

Suvretta Capital Management’s Entrada Therapeutics TRDA Stock Holding History

Suvretta Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-106,000
Closed -$1.29M – 89
2022
Q2 		$1.29M Hold
106,000
– – 0.05% 82
2022
Q1 		$995K Hold
106,000
– – 0.03% 79
2021
Q4 		$1.81M Buy
+106,000
New +$2.57M 0.04% 84

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Suvretta Capital Management's TRDA Position: Q3 2022 in Review

Suvretta Capital Management sold out of Entrada Therapeutics (TRDA) in Q3 2022, closing a stake of 106,000 shares — an estimated $1.29M sold.

Suvretta Capital Management first reported a position in TRDA in Q4 2021 and held it in 3 quarters. The position peaked at $1.81M in Q4 2021. 33 funds tracked by Wall St. Rank hold TRDA as of Q3 2022.

  • Suvretta Capital Management reported no remaining Entrada Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Suvretta Capital Management sold 106,000 Entrada Therapeutics shares in Q3 2022, an estimated $1.29M.
  • Suvretta Capital Management first reported a position in Entrada Therapeutics in Q4 2021 and held it in 3 quarters.
  • Suvretta Capital Management's Entrada Therapeutics position peaked at $1.81M in Q4 2021.
  • 33 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2022.

Based on Suvretta Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.